zilovertamab
merck
['lymsm', 'zilovertamab']
with respect to novel ror1 adc zilovertamab, cumulative neuropathy is a concerning signal. strongly recommend pro assessments of neuropathy be included in these trials, as clinician-assessed &amp; patient-reported neuropathy are not concordant: #lymsm #asco22
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????